1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient demographics with MR imaging features and PCT measurements
No. Age/Sex Contrast Enhance-ment Hemor-rhage Necro-sis Vasogenic Edema Mass Effect Signal Heterogeneity Involvement of Corpus Callosum Crossing Midline MR Grade of Tumor WHO Grade of Tumor nCBV nCBF nMTT
1 20/M HE – – + + HT + + HG I 1.92 0.58 3.55
2 27/F NCE – – + + HO – – LG II 1.07 1.48 0.83
3 34/M NCE – CD + ++ HT + + LG II 0.94 1.26 1.07
4 56/F HE – + ++ ++ HT – – HG II 1.56 1.07 1.94
5 34/F NCE – – – + HO – – LG II 1.72 1.43 1.08
6 18/F HE – + – + HT – – HG III 2.26 1.53 1.41
7 39/M HE – + + + HT – – HG III 2.21 1.23 1.71
8 57/M HE + + + +++ HT – – HG III 5.39 6.84 2.63
9 68/M NCE – + + + HT – – LG III 3.7 3.75 0.92
10 39/F HE + + ++ +++ HT + + HG III 2.61 1.65 1.68
11 34/M NCE – CD – ++ HT + + LG III 1.5 0.78 1.32
12 64/M PNE + + ++ +++ HT + + HG IV 1.96 1.19 1.78
13 39/F PNE – + ++ +++ HT + – HG IV 2.05 1.07 1.51
14 55/F PNE – + ++ +++ HT + + HG IV 3.95 2.87 1.11
15 60/M PNE + + +++ +++ HT + – HG IV 2.86 2.49 0.74
16 69/M PNE – + + ++ HT – – HG IV 1.12 1.69 1.04
17 66/F HE – + + + HT + – HG IV 5.3 6.16 0.77
18 46/M HE + + ++ ++ HT + + HG IV 4.3 6.27 0.63
19 57/M PNE – + +++ +++ HT – – HG IV 3.61 4.91 0.83
Note:—HE indicates heterogeneous enhancement; NCE, no contrast enhancement; PNE, peripheral nodular enhancement; CD, cystic degeneration; HT, heterogenous; HO, homogeneous; HG, high grade; LG, low grade; +, present; −, absent.